Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia

Inclusion Criteria: * 1.Non-menopausal females aged 18-50 years. * 2\. Body Mass Index (BMI) ≥ 18 kg/m². * 3\. Participant was diagnosed with uterine fibroids by ultrasound at the time of screening, and has one or more fibroids with a diameter of at least 2 cm (longest diameter). * 4\. Participant's menstrual cycle was ≥ 21 days and ≤ 35 days for the three consecutive months prior to screening, and the menstrual period was ≤ 14 days. * 5\. Menorrhagia due to uterine fibroids. * 6\. Agrees to use the contraceptive method specified in the protocol throughout the entire study period (from signing the informed consent form to 6 months after administration of the investigational drug). Exclusion Criteria: * 1\. Pregnant or breastfeeding female * 2\. History of childbirth within 6 months prior to screening * 3\. Excessive menstrual bleeding due to other causes or unknown reasons * 4\. Suffering from a severe coagulation disorder (e.g., hemophilia or von Willebrand disease) * 5\. Underwent myomectomy, endometrial ablation, uterine artery embolization, or magnetic resonance-guided focused ultrasound (MRgFUS)/high-intensity focused ultrasound (HIFUS) ablation within 6 months prior to screening * 6\. Underwent endometrial ablation within one year prior to screening * 7\. Severe infection, severe trauma, or major surgery within the 6 months prior to screening. * 8\. History of malignant tumors within the 5 years prior to screening (excluding cured skin cancer, basal cell carcinoma, and other localized malignant tumors). * 9\. Current or past (within 1 year) history of alcohol or drug abuse (including analgesic abuse). * 10\. Currently participating in other research projects and having used the investigational drug/treatment within 12 weeks prior to administration.